Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more
Oncolytics Biotech Inc (ONCY) - Total Assets
Latest total assets as of September 2025: $15.06 Million USD
Based on the latest financial reports, Oncolytics Biotech Inc (ONCY) holds total assets worth $15.06 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncolytics Biotech Inc - Total Assets Trend (1999–2024)
This chart illustrates how Oncolytics Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncolytics Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Oncolytics Biotech Inc's total assets of $15.06 Million consist of 93.5% current assets and 6.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.0% |
| Accounts Receivable | $68.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2024)
This chart illustrates how Oncolytics Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncolytics Biotech Inc's current assets represent 93.5% of total assets in 2024, an increase from 64.0% in 1999.
- Cash Position: Cash and equivalents constituted 79.0% of total assets in 2024, up from 63.5% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 35.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Oncolytics Biotech Inc Competitors by Total Assets
Key competitors of Oncolytics Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oncolytics Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oncolytics Biotech Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oncolytics Biotech Inc is currently not profitable relative to its asset base.
Oncolytics Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.84 | 2.99 | 12.45 |
| Quick Ratio | 1.84 | 2.99 | 12.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.40 Million | $ 15.25 Million | $ 31.03 Million |
Oncolytics Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Oncolytics Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1353.29 |
| Latest Market Cap to Assets Ratio | 5.09 |
| Asset Growth Rate (YoY) | -48.0% |
| Total Assets | $20.19 Million |
| Market Capitalization | $102.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Oncolytics Biotech Inc's assets at a significant premium ( 5.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Oncolytics Biotech Inc's assets decreased by 48.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncolytics Biotech Inc (1999–2024)
The table below shows the annual total assets of Oncolytics Biotech Inc from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $20.19 Million | -48.00% |
| 2023-12-31 | $38.82 Million | +3.98% |
| 2022-12-31 | $37.33 Million | -18.63% |
| 2021-12-31 | $45.88 Million | +33.58% |
| 2020-12-31 | $34.35 Million | +74.72% |
| 2019-12-31 | $19.66 Million | +32.24% |
| 2018-12-31 | $14.87 Million | -18.10% |
| 2017-12-31 | $18.15 Million | +22.98% |
| 2016-12-31 | $14.76 Million | -46.11% |
| 2015-12-31 | $27.38 Million | +59.27% |
| 2014-12-31 | $17.19 Million | -39.08% |
| 2013-12-31 | $28.22 Million | +27.83% |
| 2012-12-31 | $22.08 Million | -38.71% |
| 2011-12-31 | $36.02 Million | -18.92% |
| 2010-12-31 | $44.43 Million | +19.22% |
| 2009-12-31 | $37.27 Million | +166.46% |
| 2008-12-31 | $13.99 Million | -54.56% |
| 2007-12-31 | $30.78 Million | -8.29% |
| 2006-12-31 | $33.57 Million | -27.50% |
| 2005-12-31 | $46.29 Million | +17.23% |
| 2004-12-31 | $39.49 Million | +51.58% |
| 2003-12-31 | $26.05 Million | +44.98% |
| 2002-12-31 | $17.97 Million | -5.79% |
| 2001-12-31 | $19.07 Million | -11.94% |
| 2000-12-31 | $21.66 Million | +202.33% |
| 1999-12-31 | $7.16 Million | -- |